BRCA1 & BRCA2 MUTATION DRUG PROFILING PANEL (N195) - Delhi
OUTSOURCE
|
Radiology
Also Known As:
This assay detects most of the mutations and insertions/deletions in the BRCA gene which is linked to breast/ovarian cancer. Using the Oncomine Knowledge base, this assay predicts the response of drugs such as PARP inhibitors and helps to tailor the therapy. PARP inhibition results in selective killing of cancer cells which have lost BRCA1 or BRCA2 function.
-
Home Collection: Not Available
-
Reports Available: 1 Day
TAT Policy
The Turnaround Time (TAT) for a test depends on the following factors:
- Registration date and time
- Type of scan or test
- Scan time or sample collection time
Please note that in uncommon circumstances, TAT may be delayed due to the complexity of the test or reasons beyond our control. You will be informed about the estimated TAT at the time of registration or after completion of the test.
